A new model of prescription to nonprescription reclassification: the calcipotriol case study

Clinical Therapeutics
Natalie J GauldStephen Buetow

Abstract

Medicines reclassification from prescription to nonprescription (switch) has slowed in some countries, including the United States. New thinking may be necessary to drive this area, including third-party reclassification and better use of the pharmacist, collaborative care, or innovative technologies. The goal of this study was to describe a recent, successful, third-party reclassification of topical calcipotriol, a treatment for psoriasis, including the process, challenges, and solutions. This case study used multiple sources of information, including an application to the Medicines Classification Committee (MCC) in New Zealand, the response letter from the MCC, published minutes of the relevant MCC meeting, and interview data. A heuristic qualitative approach was used that embraces the involvement and experiences of the lead researcher. The third-party reclassification of topical calcipotriol generated challenges, mainly due to initial manufacturer opposition. The greatest hurdle was an inability to change the label. However, requiring mandatory pharmacist consultation, with supply under specified conditions, overcame the barriers. Such conditions included supply only to adults with mild to moderate psoriasis, limits on weekl...Continue Reading

References

Jan 23, 1999·Clinical Therapeutics·R P Juhl
Jan 23, 1999·Clinical Therapeutics·R W Soller
Jan 1, 2005·BMJ : British Medical Journal·Joshua P CohenCatherine P Cairns
Aug 21, 2007·Journal of the American Academy of Dermatology·Elizabeth J HornMark Lebwohl
Nov 26, 2008·Pharmacoepidemiology and Drug Safety·N J GauldB D Pethica
Nov 6, 2010·The Journal of Antimicrobial Chemotherapy·Natalie GauldJohn Shaw

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.